Please use this identifier to cite or link to this item: https://observatorio.fm.usp.br/handle/OPI/33989
Full metadata record
DC FieldValueLanguage
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSANTOS, Alexandra Gomes dos
dc.contributor.authorSOLLA, Davi J. Fontoura
dc.contributor.authorMOSCARDI, Ricardo
dc.contributor.authorNEVILLE, Iuri Santana
dc.contributor.authorWELTMAN, Eduardo
dc.contributor.authorTEIXEIRA, Manoel Jacobsen
dc.contributor.authorPAIVA, Wellingson Silva
dc.date.accessioned2019-11-06T18:46:42Z-
dc.date.available2019-11-06T18:46:42Z-
dc.date.issued2019
dc.identifier.citationWORLD NEUROSURGERY, v.130, p.E1015-E1019, 2019
dc.identifier.issn1878-8750
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/33989-
dc.description.abstractBACKGROUND: Most meningiomas are classified as World Health Organization (WHO) grade I. Adjuvant radiation therapy (RT) is commonly recommended for subtotal resections with documented progressive regrowth of lesions with venous sinus involvement. We investigated if recurrence of WHO grade I meningiomas was influenced by adjuvant RT. METHODS: From 2000 to 2014, patients with grade I meningiomas with at least one venous sinus involvement and at least 4 years of follow-up were included. Demographics, venous sinus involvement, histology, and extent of resection (EOR) were characterized. Because patients undergoing RT tend to differ from those for whom adjuvant therapy was not prescribed, we used propensity scores to adjust for confounding variables. RESULTS: Sixty-two patients were included; of these, 18 (29.0%) had recurrences. The mean age was 52.8 +/- 12.3 years, and 79.0% were women. A total of 34 cases (54.8%) were submitted to adjuvant RT. Adjuvant RT was more frequent in those who had tumor recurrence (77.8% vs. 45.5%, P = 0.020). RT was more frequent in superior sagittal sinus (SSS) invasion (76.5% vs. 50.0%, P = 0.030) and less prevalent after gross total resection (GTR) (32.4% vs. 67.9%, P = 0.005). Propensity score adjusted analysis suggested no adjuvant RT benefit (odds ratio [OR], 2.51; 95% confidence interval [CI], 0.68-9.28; P = 0.167), independent of the EOR. SSS involvement increased recurrence risk (OR, 12.69; 95% CI, 1.46-110.27; P = 0.021), whereas GTR tended to decrease it (OR, 0.26; 95% CI, 0.06-1.09; P = 0.065). CONCLUSIONS: Adjuvant RT does not seem to be a pivotal criterion to reduce the recurrence rate in patients with grade I meningioma, even when venous sinuses are involved.eng
dc.language.isoeng
dc.publisherELSEVIER SCIENCE INCeng
dc.relation.ispartofWorld Neurosurgery
dc.rightsrestrictedAccesseng
dc.subjectCentral nervous system neoplasmeng
dc.subjectMeningiomaeng
dc.subjectRadiation therapyeng
dc.subjectRecurrenceeng
dc.subject.otherintracranial meningiomaseng
dc.subject.otherradiation-therapyeng
dc.subject.otherirradiationeng
dc.subject.othermanagementeng
dc.subject.othersurgeryeng
dc.titleAdjuvant Radiotherapy Did Not Reduce Recurrence of World Health Organization Grade I Meningiomas with Venous Sinus Involvement: A Propensity Score Adjusted Analysis and Literature Revieweng
dc.typearticleeng
dc.rights.holderCopyright ELSEVIER SCIENCE INCeng
dc.identifier.doi10.1016/j.wneu.2019.07.068
dc.identifier.pmid31306847
dc.subject.wosClinical Neurologyeng
dc.subject.wosSurgeryeng
dc.type.categoryrevieweng
dc.type.versionpublishedVersioneng
hcfmusp.description.beginpageE1015
hcfmusp.description.endpageE1019
hcfmusp.description.volume130
hcfmusp.origemWOS
hcfmusp.origem.idWOS:000488248200125
hcfmusp.origem.id2-s2.0-85070322823
hcfmusp.publisher.cityNEW YORKeng
hcfmusp.publisher.countryUSAeng
hcfmusp.relation.referenceADEGBITE AB, 1983, J NEUROSURG, V58, P51, DOI 10.3171/jns.1983.58.1.0051eng
hcfmusp.relation.referenceARMSTRONG C, 1995, J CLIN ONCOL, V13, P2263, DOI 10.1200/JCO.1995.13.9.2263eng
hcfmusp.relation.referenceArmstrong CL, 2000, NEUROPSY NEUROPSY BE, V13, P101eng
hcfmusp.relation.referenceBARBARO NM, 1987, NEUROSURGERY, V20, P525, DOI 10.1227/00006123-198704000-00003eng
hcfmusp.relation.referenceCARELLA RJ, 1982, NEUROSURGERY, V10, P332, DOI 10.1227/00006123-198203000-00006eng
hcfmusp.relation.referenceCHAN RC, 1984, J NEUROSURG, V60, P52, DOI 10.3171/jns.1984.60.1.0052eng
hcfmusp.relation.referenceCheung VLS, 2018, J NEURO-ONCOL, V136, P351, DOI 10.1007/s11060-017-2659-6eng
hcfmusp.relation.referenceCondra KS, 1997, INT J RADIAT ONCOL, V39, P427, DOI 10.1016/S0360-3016(97)00317-9eng
hcfmusp.relation.referenceFathi AR, 2013, CURR NEUROL NEUROSCI, V13, DOI 10.1007/s11910-013-0337-4eng
hcfmusp.relation.referenceJereczek-Fossa BA, 2003, CANCER TREAT REV, V29, P417, DOI 10.1016/S0305-7372(03)00066-5eng
hcfmusp.relation.referenceKondziolka D, 2009, NEUROSURGERY, V64, P463, DOI 10.1227/01.NEU.0000336765.85922.D9eng
hcfmusp.relation.referenceLouis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4eng
hcfmusp.relation.referenceMaclean J, 2014, CLIN ONCOL-UK, V26, P51, DOI 10.1016/j.clon.2013.10.001eng
hcfmusp.relation.referenceMIRALBELL R, 1992, J NEURO-ONCOL, V13, P157, DOI 10.1007/BF00172765eng
hcfmusp.relation.referenceOhba S, 2011, J NEUROSURG, V114, P1278, DOI 10.3171/2010.11.JNS10701eng
hcfmusp.relation.referenceOstrom QT, 2018, NEURO-ONCOLOGY, V20, P1, DOI 10.1093/neuonc/noy131eng
hcfmusp.relation.referencePeele KA, 1996, OPHTHALMOLOGY, V103, P1761, DOI 10.1016/S0161-6420(96)30430-2eng
hcfmusp.relation.referencePessina F, 2019, WORLD NEUROSURG, V123, pE273, DOI 10.1016/j.wneu.2018.11.150eng
hcfmusp.relation.referencePourel N, 2001, RADIOTHER ONCOL, V61, P65, DOI 10.1016/S0167-8140(01)00391-7eng
hcfmusp.relation.referenceRogers L, 2007, NEUROSURG FOCUS, V23, pE4, DOI 10.3171/FOC-07/10/E4eng
hcfmusp.relation.referenceRuben JD, 2006, INT J RADIAT ONCOL, V65, P499, DOI 10.1016/j.ijrobp.2005.12.002eng
hcfmusp.relation.referenceSainani KL, 2012, PM&R, V4, P693, DOI 10.1016/j.pmrj.2012.07.002eng
hcfmusp.relation.referenceSIMPSON D, 1957, J NEUROL NEUROSUR PS, V20, P22, DOI 10.1136/jnnp.20.1.22eng
hcfmusp.relation.referenceSoyuer S, 2004, RADIOTHER ONCOL, V71, P85, DOI 10.1016/j.radonc.2004.01.006eng
hcfmusp.relation.referenceTAYLOR BW, 1988, INT J RADIAT ONCOL, V15, P299, DOI 10.1016/S0360-3016(98)90008-6eng
hcfmusp.relation.referenceWinther TL, 2017, WORLD NEUROSURG, V99, P104, DOI 10.1016/j.wneu.2016.11.034eng
dc.description.indexMEDLINEeng
dc.identifier.eissn1878-8769
hcfmusp.citation.scopus4-
hcfmusp.scopus.lastupdate2022-06-10-
Appears in Collections:

Artigos e Materiais de Revistas Científicas - FM/MDR
Departamento de Radiologia - FM/MDR

Artigos e Materiais de Revistas Científicas - FM/MNE
Departamento de Neurologia - FM/MNE

Artigos e Materiais de Revistas Científicas - HC/ICESP
Instituto do Câncer do Estado de São Paulo - HC/ICESP

Artigos e Materiais de Revistas Científicas - HC/ICHC
Instituto Central - HC/ICHC

Artigos e Materiais de Revistas Científicas - LIM/26
LIM/26 - Laboratório de Pesquisa em Cirurgia Experimental

Artigos e Materiais de Revistas Científicas - LIM/45
LIM/45 - Laboratório de Fisiopatologia Neurocirúrgica


Files in This Item:
File Description SizeFormat 
art_SANTOS_Adjuvant_Radiotherapy_Did_Not_Reduce_Recurrence_of_World_2019.PDF
  Restricted Access
publishedVersion (English)363.36 kBAdobe PDFView/Open Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.